Table 1 Clinical characteristics of the analyzed samples
Clinicopathological factor | N(%) |
|---|---|
Tumorsize | |
T0 | 26(11%) |
T1 | 67(28.3%) |
T2 | 35(14.8%) |
T3 | 64(27%) |
T4 | 45(18.9%) |
Unknown | 1 |
Stage | |
DCIS | 26(11.5%) |
I | 65(28.9%) |
II | 20(8.9%) |
III | 92(40.9%) |
IV | 22(9.8%) |
Unknown | 13 |
Lymphnode status | |
N0 | 114(50.7%) |
N1 | 76(34.9%) |
N2 | 32(14.4%) |
Unknown | 16 |
Grade | |
G1 | 42(17.7%) |
G2 | 128(54%) |
G3 | 67(28.3%) |
Unknown | 1 |
HER2 status | |
Negative | 60(57.1%) |
Positive | 45(42.9%) |
Unknown | 133 |
Progesteron receptor | |
Negative | 69(29.2%) |
Positive | 167(70.8%) |
Unknown | 2 |
Estrogene receptor | |
Negative | 53(22.7%) |
Positive | 180(77.3%) |
Unknown | 5 |
TP53 mutation | |
Wild type | 174(73.4%) |
Mutated | 63(26.6%) |
Unknown | 1 |
Distant metastasis | |
No distant metastasis | 214(90.3%) |
Distant metastasis | 23(9.7%) |
Unknown | 1 |
Molecular subtypes | |
Luminal A | 52(30.8%) |
Luminal B | 34(20.1%) |
ERRB2 | 29(17.2%) |
Basal | 37(21.9%) |
Normal | 17(10%) |
Unknown | 69 |